The University of Chicago Header Logo

Connection

Michael Davidson to Cardiovascular Diseases

Back to Details
This is a "connection" page, showing publications Michael Davidson has written about Cardiovascular Diseases.
Michael Davidson
Connection Strength
14.386
Cardiovascular Diseases
  1. Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials. Eur Heart J. 2026 Jul 07; 47(26):3404-3414.
    View in: PubMed
    Score: 0.583
  2. Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease. J Prev Alzheimers Dis. 2026 Jan; 13(1):100394.
    View in: PubMed
    Score: 0.555
  3. Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
    View in: PubMed
    Score: 0.550
  4. Targeting the cytoskeleton and extracellular matrix in cardiovascular disease drug discovery. Expert Opin Drug Discov. 2022 05; 17(5):443-460.
    View in: PubMed
    Score: 0.432
  5. Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: a meta-analysis. BMC Nephrol. 2022 01 16; 23(1):34.
    View in: PubMed
    Score: 0.428
  6. How I treat statin-associated side effects in an outpatient setting. Future Cardiol. 2021 10; 17(7):1249-1260.
    View in: PubMed
    Score: 0.400
  7. Recent advances and emerging therapies in management of dyslipidemias. Trends Cardiovasc Med. 2021 10; 31(7):419-424.
    View in: PubMed
    Score: 0.389
  8. Reducing residual cardiovascular risk with novel therapies. Curr Opin Lipidol. 2020 04; 31(2):108-110.
    View in: PubMed
    Score: 0.378
  9. ?-6 Polyunsaturated Fatty Acids and Cardiometabolic Health: Current Evidence, Controversies, and Research Gaps. Adv Nutr. 2018 Nov 01; 9(6):688-700.
    View in: PubMed
    Score: 0.343
  10. How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention. Curr Cardiol Rep. 2018 10 17; 20(12):138.
    View in: PubMed
    Score: 0.342
  11. Clinical trials. Curr Opin Lipidol. 2018 06; 29(3):277-278.
    View in: PubMed
    Score: 0.333
  12. Evolution of Omega-3 Fatty Acid Therapy and Current and Future Role in the Management of Dyslipidemia. Cardiol Clin. 2018 May; 36(2):277-285.
    View in: PubMed
    Score: 0.327
  13. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017 Apr; 23(Suppl 2):1-87.
    View in: PubMed
    Score: 0.307
  14. Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia. Vasc Health Risk Manag. 2016; 12:481-490.
    View in: PubMed
    Score: 0.301
  15. Using Discordance in Monozygotic Twins to Understand Causality of Cardiovascular Disease Risk Factors. JAMA Intern Med. 2016 10 01; 176(10):1530.
    View in: PubMed
    Score: 0.297
  16. Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. J Clin Lipidol. 2016 Jul-Aug; 10(4):905-914.
    View in: PubMed
    Score: 0.286
  17. Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention. Curr Atheroscler Rep. 2015 Dec; 17(12):72.
    View in: PubMed
    Score: 0.280
  18. Combination therapy with statins: who benefits? Endocrinol Metab Clin North Am. 2014 Dec; 43(4):993-1006.
    View in: PubMed
    Score: 0.261
  19. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus. Postgrad Med. 2014 May; 126(3):56-65.
    View in: PubMed
    Score: 0.251
  20. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013 Dec 10; 62(23):2178-84.
    View in: PubMed
    Score: 0.240
  21. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index =27 kg/m(2). Am J Cardiol. 2013 Apr 15; 111(8):1131-8.
    View in: PubMed
    Score: 0.230
  22. Low-density lipoprotein cholesterol, non-high-density lipoprotein, apolipoprotein, or low-density lipoprotein particle: what should clinicians measure? J Am Coll Cardiol. 2012 Dec 25; 60(25):2616-7.
    View in: PubMed
    Score: 0.228
  23. Cardio-diabetes: special considerations for the patient with diabetes and cardiovascular disease. Introduction. Am J Cardiol. 2012 Nov 06; 110(9 Suppl):1B-3B.
    View in: PubMed
    Score: 0.226
  24. Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: therapeutic approaches to improve outcomes: perspectives of a preventive cardiologist. Am J Cardiol. 2012 Nov 06; 110(9 Suppl):43B-49B.
    View in: PubMed
    Score: 0.226
  25. The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk. Curr Atheroscler Rep. 2011 Oct; 13(5):373-80.
    View in: PubMed
    Score: 0.210
  26. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011 Sep-Oct; 5(5):338-67.
    View in: PubMed
    Score: 0.208
  27. High-density lipoproteins: marker of cardiovascular risk and therapeutic target. J Clin Lipidol. 2010 Sep-Oct; 4(5):359-64.
    View in: PubMed
    Score: 0.194
  28. Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):3E-9E.
    View in: PubMed
    Score: 0.184
  29. Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol. 2009 Sep; 32(9):482-6.
    View in: PubMed
    Score: 0.182
  30. Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2009 Apr; 16(2):183-8.
    View in: PubMed
    Score: 0.176
  31. Updating the assessment of cardiac risk: beyond Framingham. Rev Cardiovasc Med. 2009; 10(2):63-71.
    View in: PubMed
    Score: 0.173
  32. Should every patient with diabetes receive a statin? Pol Arch Med Wewn. 2008 Jul-Aug; 118(7-8):398-401.
    View in: PubMed
    Score: 0.167
  33. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008 Jun 16; 101(12A):41F-50F.
    View in: PubMed
    Score: 0.167
  34. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008 Jun 16; 101(12A):51F-57F.
    View in: PubMed
    Score: 0.167
  35. High-dose statin therapy: benefits and safety in aggressive lipid lowering. J Fam Pract. 2008 May; 57(5 Suppl High-Dose):S29-36.
    View in: PubMed
    Score: 0.165
  36. Usefulness of increased skin cholesterol to identify individuals at increased cardiovascular risk (from the Predictor of Advanced Subclinical Atherosclerosis study). Am J Cardiol. 2008 Apr 01; 101(7):986-91.
    View in: PubMed
    Score: 0.163
  37. Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors. Am J Manag Care. 2007 Dec; 13 Suppl 10:S260-9.
    View in: PubMed
    Score: 0.161
  38. Effects of a reduced-glycemic-load diet on body weight, body composition, and cardiovascular disease risk markers in overweight and obese adults. Am J Clin Nutr. 2007 Mar; 85(3):724-34.
    View in: PubMed
    Score: 0.153
  39. Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease. Am Heart Hosp J. 2007; 5(4):210-6.
    View in: PubMed
    Score: 0.151
  40. Global risk management in patients with type 2 diabetes mellitus. Am J Cardiol. 2007 Feb 19; 99(4A):41B-50B.
    View in: PubMed
    Score: 0.151
  41. Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). J Cardiometab Syndr. 2006; 1(5):295-300.
    View in: PubMed
    Score: 0.141
  42. Pharmacotherapy development and trends in lipidology: An expert discussion. J Clin Lipidol. 2025 Nov-Dec; 19(6):1530-1535.
    View in: PubMed
    Score: 0.139
  43. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 Jul 03; 393(1):51-61.
    View in: PubMed
    Score: 0.135
  44. Usefulness of Carotid Ultrasound Screening in Primary Cardiovascular Prevention: A Systematic Review. Curr Probl Cardiol. 2024 Jan; 49(1 Pt C):102147.
    View in: PubMed
    Score: 0.121
  45. Smoking, Diabetes Mellitus, and Previous Cardiovascular Disease as Predictors of Anticancer Treatment-Induced Cardiotoxicity in Non-Small-Cell Lung Cancer: A Real-World Study. Clin Lung Cancer. 2024 01; 25(1):e35-e42.
    View in: PubMed
    Score: 0.120
  46. Efficacy of over-the-counter nutritional supplements. Curr Atheroscler Rep. 2003 Jan; 5(1):15-21.
    View in: PubMed
    Score: 0.114
  47. Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry. 2002; 63 Suppl 9:5-11.
    View in: PubMed
    Score: 0.107
  48. Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions. J Cardiovasc Pharmacol Ther. 2001 Jul; 6(3):219-29.
    View in: PubMed
    Score: 0.103
  49. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020 12 08; 324(22):2268-2280.
    View in: PubMed
    Score: 0.099
  50. Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol. 2021 01; 32(1):211-222.
    View in: PubMed
    Score: 0.099
  51. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med. 2000 Nov 27; 160(21):3315-25.
    View in: PubMed
    Score: 0.099
  52. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract. 2020 Oct; 26(10):1196-1224.
    View in: PubMed
    Score: 0.098
  53. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019 09; 288:85-93.
    View in: PubMed
    Score: 0.090
  54. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Atherosclerosis. 2019 09; 288:194-202.
    View in: PubMed
    Score: 0.089
  55. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clin Cardiol. 2018 Oct; 41(10):1281-1288.
    View in: PubMed
    Score: 0.085
  56. Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. J Am Heart Assoc. 2018 09 18; 7(18):e009221.
    View in: PubMed
    Score: 0.085
  57. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARYComplete Appendix to Guidelines available at http://journals.aace.com. Endocr Pract. 2017 Apr 02; 23(4):479-497.
    View in: PubMed
    Score: 0.076
  58. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13; 134(24):1931-1943.
    View in: PubMed
    Score: 0.074
  59. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. Lipids Health Dis. 2015 Sep 02; 14:98.
    View in: PubMed
    Score: 0.069
  60. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015 Apr; 21(4):438-47.
    View in: PubMed
    Score: 0.067
  61. Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy. Cardiovasc Drugs Ther. 2015 Feb; 29(1):41-50.
    View in: PubMed
    Score: 0.066
  62. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014 Dec 16; 64(23):2525-40.
    View in: PubMed
    Score: 0.065
  63. [Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary]. Clin Investig Arterioscler. 2014 Jan-Feb; 26(1):33-7.
    View in: PubMed
    Score: 0.061
  64. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013 Sep; 35(9):1400-11.e1-3.
    View in: PubMed
    Score: 0.060
  65. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J. 2013 Apr; 34(13):962-71.
    View in: PubMed
    Score: 0.058
  66. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res. 2012 Oct; 51(4):314-24.
    View in: PubMed
    Score: 0.055
  67. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk. Diabetes Obes Metab. 2012 Jan; 14(1):30-9.
    View in: PubMed
    Score: 0.053
  68. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis. 2010 Nov; 213(1):1-7.
    View in: PubMed
    Score: 0.047
  69. Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence. J Clin Lipidol. 2010 Jan-Feb; 4(1):72-3; discussion 74.
    View in: PubMed
    Score: 0.046
  70. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther. 2009 Dec; 31(12):2824-38.
    View in: PubMed
    Score: 0.046
  71. ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2009 Sep 29; 54(14):1336-63.
    View in: PubMed
    Score: 0.046
  72. ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association. Circulation. 2009 Sep 29; 120(13):e100-26.
    View in: PubMed
    Score: 0.046
  73. The editor's roundtable: the JUPITER trial--initial results and clinical implications. Am J Cardiol. 2009 May 15; 103(10):1417-25.
    View in: PubMed
    Score: 0.044
  74. The editor's roundtable: lipid management beyond statins-reducing residual cardiovascular risk. Am J Cardiol. 2008 Sep 01; 102(5):559-67.
    View in: PubMed
    Score: 0.042
  75. The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med. 2008 Oct; 5(10):621-35.
    View in: PubMed
    Score: 0.042
  76. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008 Apr 15; 51(15):1512-24.
    View in: PubMed
    Score: 0.041
  77. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008 Apr; 31(4):811-22.
    View in: PubMed
    Score: 0.041
  78. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008 Mar; 6(3):391-409.
    View in: PubMed
    Score: 0.041
  79. Impaired diurnal blood pressure variation and all-cause mortality. Am J Hypertens. 2008 Jan; 21(1):92-7.
    View in: PubMed
    Score: 0.040
  80. Type 2 diabetes and cardiovascular disease: reducing the risk. J Manag Care Pharm. 2007 Mar; 13(2 Suppl A):S2-15; quiz S16-7.
    View in: PubMed
    Score: 0.038
  81. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther. 2006 Jul; 4(4):461-76.
    View in: PubMed
    Score: 0.036
  82. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation. 2005 Aug 30; 112(9):1289-95.
    View in: PubMed
    Score: 0.034
  83. A genetic and epidemiologic study of cardiovascular disease in Alaska natives (GOCADAN): design and methods. Int J Circumpolar Health. 2005 Jun; 64(3):206-21.
    View in: PubMed
    Score: 0.034
  84. Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis. Alzheimers Res Ther. 2024 10 16; 16(1):228.
    View in: PubMed
    Score: 0.032
  85. Combination therapy in the management of complex dyslipidemias. Curr Opin Lipidol. 2004 Aug; 15(4):423-31.
    View in: PubMed
    Score: 0.032
  86. Cardiovascular disease among Alaska Natives: a review of the literature. Int J Circumpolar Health. 2003 Dec; 62(4):343-62.
    View in: PubMed
    Score: 0.030
  87. The role of cardiovascular risk factors in Alzheimer's disease. CNS Spectr. 2003 Nov; 8(11):824-33.
    View in: PubMed
    Score: 0.030
  88. A cross-sectional study of lipids and ApoC levels in Alzheimer's patients with and without cardiovascular disease. J Gerontol A Biol Sci Med Sci. 2002 Nov; 57(11):M757-61.
    View in: PubMed
    Score: 0.028
  89. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry. 2002; 63 Suppl 9:25-9.
    View in: PubMed
    Score: 0.027
  90. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999 Jan 20; 281(3):235-42.
    View in: PubMed
    Score: 0.022
  91. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial. J Clin Lipidol. 2018 Mar - Apr; 12(2):321-330.
    View in: PubMed
    Score: 0.020
  92. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia. J Clin Lipidol. 2016 Nov - Dec; 10(6):1442-1451.e4.
    View in: PubMed
    Score: 0.018
  93. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf. 2015 Jun; 14(6):935-55.
    View in: PubMed
    Score: 0.017
  94. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013 Sep-Oct; 7(5):484-525.
    View in: PubMed
    Score: 0.015
  95. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr; 19(2):327-36.
    View in: PubMed
    Score: 0.014
  96. Effects of high-fiber oat and wheat cereals on postprandial glucose and lipid responses in healthy men. Int J Vitam Nutr Res. 2007 Sep; 77(5):347-56.
    View in: PubMed
    Score: 0.010
  97. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006 Dec 06; 296(21):2572-81.
    View in: PubMed
    Score: 0.009
  98. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006 Mar 23; 354(12):1253-63.
    View in: PubMed
    Score: 0.009
  99. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol. 2005 Nov; 46(5):594-9.
    View in: PubMed
    Score: 0.009
  100. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004; 65 Suppl 7:4-18; quiz 19-20.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.